Drugs in Context, 2022 The therapeutic approach to patients affected by advanced non-small-cell lung cancer (NSCLC) is facing rapid and continuous evolution. In recent years, the emergence of new treatment strategies, such as immunotherapy and tyrosine kinase inhibitors, has ...
Andrea De Giglio +5 more
doaj +1 more source
Patterns of CT lung injury and toxicity after stereotactic radiotherapy delivered with helical tomotherapy in early stage medically inoperable NSCLC [PDF]
, 2015 To evaluate toxicity and patterns of radiologic lung injury on CT images after hypofractionated image-guided stereotactic body radiotherapy (SBRT) delivered with helical tomotherapy (HT) in medically early stage inoperable non-small-cell lung cancer ...
Agolli, Linda +9 more
core +1 more source
SINGLE AGENT DOCETAXEL AS SECOND- LINE CHEMOTHERAPY FOR PRETREATED PATIENTS WITH RECURRENT NON- SMALL CELL LUNG CANCER [PDF]
, 2013 Objective: Single agent Docetaxel is a standard therapy for patients with non- small cell lung cancer after the failure of platinum- containing regimens.
Deyan N. Davidov
core +1 more source
Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer
Chinese Journal of Lung Cancer, 2021 Lung cancer is one of the malignant tumors with the highest morbidity and mortality in the world. Immune checkpoint inhibitors (ICIs), including programmed cell death 1 (PD-1) antibody, programmed cell death ligand 1 (PD-L1) antibody, and cytotoxic T ...
Chinese Society of Clinical Oncology, Expert Committee on Tumor Vascular-targeted Therapy +1 more
doaj +1 more source
Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer? [PDF]
, 2014 Immunotherapy has been studied for many years in lung cancer without significant results, making the majority of oncologists quite skeptical about its possible application for non-small cell lung cancer treatment.
Annelies Janssens +52 more
core +1 more source
MicroRNA-24 in Cancer: A Double Side Medal With Opposite Properties
Frontiers in Oncology, 2020 MicroRNA-24 (miR-24) has been widely studied in a variety of human cancers, which plays different roles in specific type of cancers. In the present review, we summarized the recent surveys regarding the role of miR-24 in different human cancers.
Sumei Wang +18 more
doaj +1 more source
Non-small-cell lung cancer: how to manage RET-positive disease
Drugs in Context, 2022 Targeted therapy has dramatically changed the history and outcomes of oncogene-addicted non-small-cell lung cancer (NSCLC). RET rearrangements are typically observed in about 1–2% of NSCLC, resulting in constitutive activation of downstream signalling ...
Elisa Andrini +6 more
doaj +1 more source
Overexpression of the non-coding SOX2OT variants 4 and 7 in lung tumors suggests an oncogenic role in lung cancer [PDF]
, 2016 Despite the advances in cancer therapy, lung cancer still remains the most leading cause of cancer death worldwide. The long non-coding RNAs (lncRNAs) are recently introduced as novel regulators of human cancers. SOX2 overlapping transcript (SOX2OT) is a
Ghanei, M. +4 more
core +1 more source
Non-small-cell lung cancer: how to manage EGFR-mutated disease
Drugs in Context, 2022 The treatment of non-small-cell lung cancer (NSCLC) harbouring EGFR mutations has witnessed some major breakthroughs in the last years. On the one hand, the recent advent of the third-generation tyrosine kinase inhibitor (TKI) osimertinib has reshaped ...
Federica Pecci +6 more
doaj +1 more source
MYC is a metastasis gene for non-small-cell lung cancer. [PDF]
, 2009 Metastasis is a process by which cancer cells learn to form satellite tumors in distant organs and represents the principle cause of death of patients with solid tumors. NSCLC is the most lethal human cancer due to its high rate of metastasis.
Castro, Inês +8 more
core +8 more sources